Mobara, Japan

Miwa Ikeda

This inventor holds 1 USPTO granted patent. Top assignee: Mitsui Chemicals, Inc.. Active years: 2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Miwa Ikeda. Retrieved from https://idiyas.com/inventor/miwa-ikeda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Miwa Ikeda: Innovator in Exosome Research

Introduction

Miwa Ikeda is a prominent inventor based in Mobara, Japan. She has made significant contributions to the field of biotechnology, particularly in the area of exosome research. Her innovative work has led to the development of methods that could have a profound impact on medical science.

Latest Patents

Miwa Ikeda holds a patent for a "Method for destroying exosomes, kit for destroying exosomes, and method for isolating exosomes derived from normal cells." This patent describes a method that includes a step of preparing an antimicrobial peptide and a step of allowing the antimicrobial peptide to coexist with an exosome to destroy the exosome. This groundbreaking approach could pave the way for new therapeutic strategies.

Career Highlights

Ikeda is currently employed at Mitsui Chemicals, Inc., where she continues to advance her research. Her work is characterized by a commitment to innovation and excellence in the field of biotechnology. She has been recognized for her contributions and is regarded as a leader in her area of expertise.

Collaborations

Miwa Ikeda collaborates with talented colleagues, including Ryota Fujii and Kazuya Matsumoto. Together, they work on various projects that aim to enhance the understanding and application of exosome technology.

Conclusion

Miwa Ikeda's contributions to exosome research exemplify the spirit of innovation in biotechnology. Her work not only advances scientific knowledge but also holds promise for future medical applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…